Despite the promise of TLR agonists as potential anticancer agents, few have reached the clinics due to concerns related to cytokine release syndrome and limited efficacy. Intratumoral mRNA encoding ...
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could presage further deals in STAT6, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback